Accelerate Diagnostics Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Accelerate Diagnostics stock.
View analyst ratings for Accelerate Diagnostics or view top-rated stocks.

Wall Street analysts have given Accelerate Diagnostics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Accelerate Diagnostics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Accelerate Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Accelerate Diagnostics.

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) issued its quarterly earnings results on Monday, February, 22nd. The medical research company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by $0.01. The medical research company earned $3.10 million during the quarter, compared to analysts' expectations of $3.10 million.
View Accelerate Diagnostics' earnings history.

Accelerate Diagnostics' stock was trading at $10.61 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AXDX shares have decreased by 23.8% and is now trading at $8.08.
View which stocks have been most impacted by COVID-19.

3 equities research analysts have issued 1-year price targets for Accelerate Diagnostics' shares. Their forecasts range from $15.00 to $20.00. On average, they anticipate Accelerate Diagnostics' stock price to reach $17.50 in the next twelve months. This suggests a possible upside of 116.6% from the stock's current price.
View analysts' price targets for Accelerate Diagnostics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Accelerate Diagnostics include Bionano Genomics (BNGO), Fluidigm (FLDM), EyePoint Pharmaceuticals (EYPT), Harvard Bioscience (HBIO), Precipio (PRPO), Scientific Industries (SCND), HTG Molecular Diagnostics (HTGM), Astrotech (ASTC), Pressure BioSciences (PBIO), BioForce Nanosciences (BFNH), Arrayit (ARYC), DiaSys (DYXC), HORIBA (HRIBF), Orthometrix (OMRX) and PositiveID (PSID).
View all of AXDX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), MagnaChip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AT&T (T), AbbVie (ABBV) and Micron Technology (MU).

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

Accelerate Diagnostics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Chicago Capital LLC (2.60%). Company insiders that own Accelerate Diagnostics stock include Jack W Schuler, Romney Humphries and Steven Reichling.
View institutional ownership trends for Accelerate Diagnostics.

AXDX stock was sold by a variety of institutional investors in the last quarter, including Chicago Capital LLC. Company insiders that have sold Accelerate Diagnostics company stock in the last year include Romney Humphries, and Steven Reichling.
View insider buying and selling activity for Accelerate Diagnostics or view top insider-selling stocks.

Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AXDX stock can currently be purchased for approximately $8.08.

Accelerate Diagnostics has a market capitalization of $494.71 million and generates $9.30 million in revenue each year. The medical research company earns $-84,310,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis.

Accelerate Diagnostics employs 275 workers across the globe.

The official website for Accelerate Diagnostics is acceleratediagnostics.com.

Accelerate Diagnostics is headquartered at 3950 South Country Club Suite 470, Tucson AZ, 85714.

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at 520-365-3100 or via email at [email protected]